The global Antihyperlipidemic Drugs market is estimated to attain a valuation of US$ 20.1 Bn by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 6.1% during the forecast period, 2022-2031.
The key objective of the TMR report is to offer a complete assessment of the global market...
The Antihyperlipidemic Drugs Market is estimated to be valued at US$ 12.6 Bn in 2022 and is expected to exhibit a CAGR of 7.5% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.Market Overview: Antihyperlipidemic drugs are used to lower and control the levels of lipids, such as cholesterol and triglycerides, in the blood. These drugs are...
SWOT Analysis
Strengths: Drugs in this market such as statins are highly effective in lowering LDL cholesterol levels and reducing the risk of heart attacks and strokes. The market comprises several major pharmaceutical players with wide distribution networks. Weaknesses: Statins have certain side effects such as muscle pain and are not suitable for all patients. Generic competition has eroded...
The global Antihyperlipidemic Drugs Market is estimated to be valued at US$ 13.6 Bn in 2023 and is expected to exhibit a CAGR of 7.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Antihyperlipidemic drugs are commonly known as lipid lowering drugs or statins which reduce cholesterol and triglyceride levels in the blood. These...
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Romaian